DaVita Inc. (NYSE:DVA) Receives Average Rating of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have received an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $199.1667.

Several equities research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. TD Cowen lifted their price objective on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. UBS Group lifted their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Truist Financial lifted their price objective on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th.

DaVita Trading Down 0.2%

Shares of NYSE DVA opened at $208.31 on Wednesday. The stock has a market cap of $13.37 billion, a P/E ratio of 19.32, a PEG ratio of 0.68 and a beta of 0.91. The business’s fifty day simple moving average is $176.13 and its 200-day simple moving average is $146.28. DaVita has a 12-month low of $101.00 and a 12-month high of $211.80.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts forecast that DaVita will post 15.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of DaVita

A number of large investors have recently made changes to their positions in DVA. NewEdge Advisors LLC increased its holdings in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Goldman Sachs Group Inc. boosted its stake in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares during the period. Cerity Partners LLC grew its position in DaVita by 7.0% during the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock worth $376,000 after purchasing an additional 172 shares during the last quarter. Bank of Nova Scotia increased its stake in DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after purchasing an additional 176 shares during the period. Finally, Natixis raised its holdings in shares of DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after buying an additional 3,264 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.